CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 165 enrolled
Drug / intervention
Panax Ginseng +2 moredrug
Likely dose
Panax Ginseng 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01375114
NCT01375114Phase 2Active
CompareCT.gov

The Effects of Ginseng on Cancer-Related Fatigue

M.D. Anderson Cancer Center·interventional·Posted Jun 17, 2011·Updated May 4, 2026

In Brief

A Phase 2 clinical trial evaluating Panax Ginseng, Placebo, and 1 other intervention for Advanced Cancers and Solid Tumors. Active but no longer recruiting, targeting 165 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if panax ginseng (commonly called ginseng) can help to control fatigue and other symptoms such as depression, anxiety, and mood changes in patients with cancer. The safety of ginseng will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancers, Solid Tumors
CountriesUnited States
CollaboratorsIndena S.p.A

Timeline

Phase 2Active
2011201220132014201520162017201820192020202120222023202420252026202720282029
First PostedJun 17, 2011
Enrollment StartOct 14, 2011
Primary CompletionMay 15, 2016
Study CompletionOct 31, 2028
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 15.0 years ago

Interventions

Panax Ginsengdrug

400 mg by mouth twice daily from Day 1-29.

Placebodietary

Placebo by mouth twice daily for 4 weeks.

Questionnairesbehavioral

Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.